CXCL12 treatment of prostate cancer cells results in increased αvβ3 expression and receptor affinity, which enhances cell adhesion to human bone marrow cells [97] and their ability to bind to the ECM protein vitronectin [99]. This evidence concerns the gene CXCL12 and prostate carcinoma.